DOM-METOPROLOL-L TABLET
Država: Kanada
Jezik: angleščina
Source: Health Canada
Lastnosti izdelka
(SPC)
06-10-2016
Nekateri dokumenti za ta izdelek trenutno niso na voljo, pošljete lahko zahtevo v našo stranko in obvestili vas bomo takoj, ko jih bomo lahko pridobili.
Pošlji zahtevo.
Pošlji zahtevo.
Aktivna sestavina:
METOPROLOL TARTRATE
Dostopno od:
DOMINION PHARMACAL
Koda artikla:
C07AB02
INN (mednarodno ime):
METOPROLOL
Odmerek:
50MG
Farmacevtska oblika:
TABLET
Sestava:
METOPROLOL TARTRATE 50MG
Pot uporabe:
ORAL
Enote v paketu:
300
Tip zastaranja:
Prescription
Terapevtsko območje:
BETA-ADRENERGIC BLOCKING AGENTS
Povzetek izdelek:
Active ingredient group (AIG) number: 0111923002; AHFS:
Status dovoljenje:
APPROVED
Datum dovoljenje:
1997-04-24
Lastnosti izdelka
PRODUCT MONOGRAPH
PR
DOM-METOPROLOL-L
Metoprolol Tartrate Tablets, USP
25 mg, 50 mg and 100 mg
Β-ADRENERGIC RECEPTOR BLOCKING AGENT
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
DATE OF REVISION:
September 27, 2016
SUBMISSION CONTROL NO: 197897
_Dom-METOPROLOL-L Product Monograph _
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE
REACTIONS..................................................................................................
10
DRUG INTERACTIONS
..................................................................................................
13
DOSAGE AND ADMINISTRATION
..............................................................................
17
OVERDOSAGE
................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 20
STORAGE AND STABILITY
..........................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 24
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL
INFORMATION..........................................................................
25
DETAILED PHARMACOLOGY
.....................................................................................
26
TOXICOLOGY
.........................................
Preberite celoten dokument
